RO7669330
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for RO7669330, covering 2026-04-03 to 2026-04-03. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) [Phase 1]